Dr. Mohammad Kamal Featured in Roche Webinar Series
Beyond the Cervix: Unmasking Anal and Oral HPV Cancers
As part of Roche’s educational webinar series, Beyond the Cervix: Unmasking Anal and Oral HPV Cancers, Dr. Mohammad Kamal, CEO of OmniPathology, presented emerging data on the growing public health challenge posed by HPV-associated cancers beyond the cervix, with a particular focus on oropharyngeal (throat) cancer.
During the webinar, Dr. Kamal highlighted the dramatic rise in HPV-related throat cancers, which are now among the fastest-growing HPV-associated malignancies. These cancers are most commonly linked to persistent infection with high-risk strains of human papillomavirus (HPV), underscoring the importance of early identification and ongoing monitoring of at-risk individuals.
HPV is one of the most common sexually transmitted infections worldwide. While most infections resolve naturally, persistent infection with high-risk HPV types can lead to the development of cancer over time. Individuals with multiple lifetime sexual partners, compromised immune systems, or a history of HPV-related disease may face an increased risk of persistent infection and subsequent cancer development.
A key point of discussion was the significant gender disparity in HPV-associated throat cancer, which occurs approximately five times more frequently in men than in women. Dr. Kamal also reviewed evidence demonstrating that women with HPV-related cervical disease are at elevated risk for anal cancer, and that partners of individuals with HPV infection may be at increased risk for developing oropharyngeal cancer.
The presentation emphasized that persistent high-risk HPV infection is one of the strongest indicators of future cancer risk. Identifying these infections before symptoms develop provides an important opportunity for closer clinical surveillance and specialist evaluation. Patients who test positive for persistent oropharyngeal HPV should discuss appropriate follow-up care with their healthcare provider, which may include evaluation by an ear, nose, and throat (ENT) specialist.
To address the need for improved screening and risk assessment, OmniPathology has developed a proprietary, patent-pending oropharyngeal HPV swab test designed to detect 14 high-risk HPV types associated with cancer risk. This non-invasive test is intended to help identify individuals who may benefit from additional monitoring and clinical follow-up.
As awareness of HPV-associated cancers continues to grow, advances in testing and early detection are playing an increasingly important role in helping clinicians identify patients at elevated risk and potentially improve outcomes through earlier intervention.
Additional information about OmniPathology’s oropharyngeal HPV testing program and ordering information is available at OmniOP2.com.
